

RECEIVED
APR 24 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900



In re Application of:

Liu, Ya Fang

Serial No: 10/042,614

Filed: Januray 9, 2002

For: Method for Identifying JNK and MLK
Inhibitors for Treatment of Neurological
Conditions

Attorney Docket No. YFLU-P03-001

Art Unit: 1631

Examiner: N/A

#3
Plunkett
5/1/02

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

4/11/02

Date of Signature
and of Mail Deposit

Anna P. Lucey
Anna P. Lucey

Assistant Commissioner for Patents
United State Patent and Trademark Office
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT IN COMPLIANCE WITH 37

CFR §§ 1.97(b) and 1.98(d)

Submitted herewith on Form PTO-1449 is a list of publications cited in the parent application (U.S.S.N. 09/156,367, filed September 17, 1998) of the above-referenced application. In accordance with CFR § 1.98 (d), applicants respectfully submit that *no copy* of any patent, publication, or other information listed on the enclosed Form PTO 1449 is needed because the citations were made in the above-mentioned parent application which is relied upon for an earlier filing date under 35 U.S.C. 120.

This Information Disclosure Statement is being filed before the mailing of the first office action on the merits; therefore, no fee is due.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits, and as such applicants believe no fees are due at this time. However, should any fees need to be paid in connection with this submission, the Commissioner is hereby authorized to credit any overpayment or charge any deficiency to/from **Deposit Account No. 18-1945**, under Order No. YFLU-P03-001.

Respectfully submitted,
Ropes & Gray

By: William G. Gosz
William G. Gosz
Reg. No. 27,787

Dated: 4/9/02
Customer No. 28120
Ropes & Gray
Patent Group
One International Place
Boston, MA 02110-2624

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
YFLU-P03-001Application Number
10/042,614Applicant
Liu, Ya FangFiling Date
January 9, 2002Group Art Unit
1631COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,060,247	5/00	Miller et al.		
	AB	5,854,043	12/98	Johnson		
	AC	5,840,509	11/98	Ni et al.		
	AD	5,817,479	10/98	Au-Young et al.		
	AE	5,741,808	4/21/98	Lewis et al.		
	AF	5,621,100	4/15/97	Lewis et al.		
	AG	5,621,101	4/15/97	Lewis et al.		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	AH	WO 9918193	4/15/99	WIPO			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AI	Anderson, A. J. et al. DNA Damage and Apoptosis in Alzheimer's Disease: Colocalization with c-Jun Immunoreactivity, Relationship to Brain Area, and Effect of Postmortem Delay. <i>J. Neurosci.</i> 16, 1710-1719 (1 March 1996).
AJ	Bossy-Wetzel, E. et al. Induction of Apoptosis by the Transcription Factor c-Jun. <i>EMBO J.</i> 16, 1695-1709 (1997).
AK	Chen, Y. et al. The Role of c-Jun N-Terminal Kinase (JNK) in Apoptosis Induced by Ultraviolet C and γ Radiation. <i>J. Biol. Chem.</i> 271, 31929-31936 (13 December 1996).
AL	Cheung, N. S. et al. Kainate-induced apoptosis correlates with c-Jun activation in cultured cerebellar granule cells. <i>J. Neurosci. Res.</i> 52, 69-82 (1 April 1998).
AM	David, G. et al. Cloning of the SCA7 Gene Reveals a Highly Unstable CAG Repeat Expansion. <i>Nature Genetics</i> 17, 65-70 (September 1997).
AN	Davis, R. J. Human JNK3 Alpha 2 Protein Kinase (JNK3A2) mRNA. <i>GenBank</i> Accession No. U33819
AO	Davis, R. J. Human JNK3 Alpha 2 Protein Kinase (JNK3A2) mRNA. <i>GenBank</i> Accession No. U33820.
AP	Davis, R. J. MAPKs: New JNK Expands the Group. <i>TIBS</i> 19, 470-473 (November 1994).
AQ	Derijard, B. et al. JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain. <i>Cell</i> 76, 1025-1037 (25 March 1994).
AR	Dickens, M. et al. A Cytoplasmic Inhibitor of JNK Signal Transduction Pathway. <i>Science</i> 277, 693 (1 August 1997).

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)

YFLU-P03-001

Applicant

Liu, Ya Fang

Filing Date

January 9, 2002

Application Number

10/042,614

**COPY OF PAPERS
ORIGINALLY FILED**

AS	Doroshenko, Donna S. et al. Complete Nucleotide Sequence, Expression, and Chromosomal Localization of Human Mixed-Lineage Kinase 2. <i>Eur. J. Biochem.</i> 234, 492-500 (1995).
AT	Duyao, M. et al. Trinucleotide Repeat Length Instability and Age of Onset in Huntington's Disease. <i>Nature Genetics</i> 4, 387-392 (August 1993).
AU	Eilers, A. et al. Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons. <i>J. Neurosci.</i> 18, 1713-1724 (1 March 1998).
AV	Gallo, K. A. et al. Identification and Characteristics of SPRK, a Novel src-Homology 3 Domain-containing Proline-rich Kinase with Serine/Threonine Kinase Activity. <i>J. Biol. Chem.</i> 269, 15092-15100 (27 May 1994).
AW	Goodenough et al. <i>Society for Neurological Abstracts</i> 23, 1387 (October 1997).
AX	Gupta, S. et al. Selective Interaction of JNK Protein Kinase Isoforms with Transcription Factors. <i>EMBO J.</i> 15, 2760-2770 (1996).
AY	Ham, J. et al. A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death. <i>Neuron.</i> 14, 927-939 (May 1995).
AZ	Herdegen, T. et al. Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury. <i>J. Neurosci.</i> 18, 5124-5135 (15 July 1998).
BA	Hirai, S. et al. MST/MLK2, a Member of the Mixed Lineage Kinase Family, Directly Phosphorylates and Activates SEK1, an Activator of c-Jun N-terminal Kinase/Stress-activated Protein Kinase. <i>J. Biol. Chem.</i> 272, 15167-15173 (13 June 1997).
BB	The Huntington's Disease Collaborative Research Group. A Novel Gene Containing a Trinucleotide Repeat that is Expanded and Unstable on Huntington's Disease Chromosomes. <i>Cell</i> 72, 971-983 (26 March 1993).
BC	Kyriakis, J. M. et al. The Stress-Activated Protein Kinase Subfamily of c-Jun Kinases. <i>Nature</i> 369, 156-160 (12 May 1994).
BD	Lin, A. et al. Identification of a Dual Specificity Kinase that Activates the Jun Kinases and p38-Mpk2. <i>Science</i> 268, 286-290 (14 April 1995).
BE	Liu, Ya Fang. Expression of Polyglutamine-expanded Huntington Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line. <i>J. Biol. Chem.</i> 273, 28873-77 (23 October 1997).
BF	Liu, Ya Fang et al. Expression of the Huntington Mutant Activates JNK/SAPK and Induces Neuronal Apoptosis. <i>Society for Neurosci. Abstracts</i> 23, 1909 (25 October 1997) - ABSTRACT XP002115942.
BG	Liu, Ya Fang et al. SH3 Domain-dependent Association of Huntington with Epidermal Growth Factor Receptor Signaling Complexes. <i>J. Biol. Chem.</i> 272, 8121-8124 (28 March 1997).
BH	Liu, Z. et al. Dissection of TNF Receptor 1 Effector Functions: JNK Activation is Not Linked to Apoptosis While NF-KB Activation Prevents Cell Death. <i>Cell</i> 87, 565-576 (November 1996).
BI	Maroney, Anna C. et al. Mononeuron Apoptosis is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway. <i>J. Neurosci.</i> 18, 104-111 (1 January 1998).

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

YFLU-P03-001

Application Number

10/042,614

Applicant

Liu, Ya Fang

Filing Date

January 9, 2002

Group Art Unit

1631

COPY OF PAPERS
ORIGINALY FILED

BJ

Martin, J. H. et al. Developmental Expression in the Mouse Nervous System of the p493F12 SAP Kinase. *Brain Res. Mol. Brain Res.* 35, 47-57 (January 1996) - ABSTRACT ONLY.

BK

Nagafuchi, S. et al. Structure and Expression of the Gene Responsible for the Triplet Repeat Disorder, Dentatorubral and Pallidolysian Atrophy (DRPLA). *Nature Genetics* 8, 177-182 (October 1994).

BL

Nishina, H. et al. Stress Signaling Kinase Sek1 Protects Thymocytes from Apoptosis Mediated by CD95 and CD3. *Nature* 385, 350-357 (23 January 1997).

BM

Paulson, H. L. et al. Trinucleotide Repeats in Neurogenetic Disorders. *An. Rev. Neurosci.* 19, 79-107 (1996).

BN

Rana, A. et al. The Mixed Lineage Kinase SPRK Phosphorylates and Activates the Stress-activated Protein Kinase Activation SEK-1. *J. Biol. Chem.* 271, 19025-19028 (9 August 1996).

BO

Schwarzschild, M. A. et al. Glutamate, But Not Dopamine, Stimulates Stress-Activated Protein Kinase and AP-1 Medicated Transcription in Striatal Neurons. *J. Neurosci.* 17, 3455-3466 (15 May 1997).

BP

Snell, R. et al. Relationship Between Trinucleotide Repeat Expansion and Phenotypic Variation in Huntington's Disease. *Nature* 4, 393-397 (August 1993).

BQ

Thomas, L. B. et al. DNA End Labeling (TUNEL) in Huntington's Disease and other Neuropathological Conditions. *Exp. Neurol.* 133, 265-272 (June 1995) - ABSTRACT ONLY.

BR

Tibbles et al. MLK-3 activates the SAPK/JNK and p378/RK pathways via SEK1 and MKK3/6. *EMBO J.* 15, 7026-7035 (1996).

BS

Virdee, K. et al. Composition Between the Timing of JNK Activation, c-Jun Phosphorylation, and Onset of Death Commitment in Sympathetic Neurons. *J. Neurochem.* 69, 550-561 (1997).

BT

Yan et al. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. *Nature* 372, 798-300 (December 1994).

BU

Yang, D. D. et al. Absence of Excitotoxicity-Induced Apoptosis in the Hippocampus of Mice Lacking the Jnk3 Gene. *Nature* 389, 865-870 (23 October 1997).

BV

Yardin, C. et al. FK506 antagonizes apoptosis and c-jun protein expression in neuronal cultures. *Neuroreport* 9, 2077-80 (22 June 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED

APR 24 2002

TECH CENTER 1600/2900